---
title: "Vitruvias Therapeutics: Thyroid Tablets, USP 30 mg — FDA announcement Aug 24, 2026 | Is It on Recall"
description: "Potential for the Product to be Superpotent"
url: https://isitonrecall.com/recall/fdapress-19092c9309b8774e-vitruvias-therapeutics-thyroid-tablets-usp-30-mg/
updated: 2026-10-01
site: "Is It on Recall"
language: en
---

[Recall archive](https://isitonrecall.com/archives/) / FDA company announcement

# Vitruvias Therapeutics: Thyroid Tablets, USP 30 mg — FDA announcement Aug 24, 2026

Published notice; closure not supplied

A company announcement posted by FDA. The listing date can differ from the original announcement date. The absence of a termination marker does not prove the recall is currently ongoing.

Source date Aug 24, 2026. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.

Archive changed Oct 1, 2026. USDA FSIS records are unavailable; [check FSIS directly](https://www.fsis.usda.gov/recalls). [Source coverage and dates](https://isitonrecall.com/sources/).

## What the record says

- **Product**: Thyroid Tablets, USP 30 mg
- **Reason**: Potential for the Product to be Superpotent
- **Classification**: Not supplied
- **Recalling firm**: Vitruvias Therapeutics, Inc
- **Quantity**: Not supplied
- **Agency-reported status**: Company recall announcement
- **Source record identifier**: 19092c9309b8774e

[Open the official record](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential)

## Lot and product identifiers

| Label field | Details supplied by the agency |
| --- | --- |
| Lot, code or applicability | AUBURN, Ala. (August 21, 2026) – Vitruvias Therapeutics Inc. is voluntarily recalling one lot (Lot. No. 504950) of Thyroid Tablets, USP 30 mg to the consumer level. The product is being recalled because testing confirmed the potential for the product to be superpotent.; To best identify the product, the NDC, Product Description, Lot Number, and Expiration Date are listed below.; Lot 504950 was distributed nationwide in the USA to Vitruvias Therapeutics' direct accounts from Jan. 31, 2025 to Sept. 30, 2025.; Vitruvias Therapeutics is proactively notifying its wholesalers by email and phone to discontinue distribution of the product being recalled and is arranging for destruction of all recalled product. Patients who are currently taking Thyroid, USP from Lot 504950, which is being recalled, should not discontinue use without contacting their healthcare provider for further guidance and/or a replacement prescription.; Product \| NDC \| Lot \| Exp Date \| Units Released \| Units Sold \| First Distribution Date \| Last Distribution Date; Thyroid Tablets, USP 30 mg \| 69680- 166-00 \| 504950 \| 9/30/2026 \| 3,655 \| 1955 \| 1/31/2025 \| 9/30/2025 |

Match all identifying details in the current notice. A brand name alone is not enough.

## Product tables from the announcement

These identifying details come from the company announcement posted by FDA. Check the current notice for revisions.

**FDA company announcement, table 1**

| Product | NDC | Lot | Exp Date | Units Released | Units Sold | First Distribution Date | Last Distribution Date |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Thyroid Tablets, USP 30 mg | 69680- 166-00 | 504950 | 9/30/2026 | 3,655 | 1955 | 1/31/2025 | 9/30/2025 |

Announcement retrieved Oct 1, 2026. [Official announcement](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential).

## Distribution

Not supplied

No US distribution state could be established from this record. Check the official notice.

## Dates in the source

- **Fda listing date**: Aug 24, 2026
- **Company announcement date**: Aug 21, 2026

FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.

## What to do next

Consumers with questions about the recall can contact Vitruvias Therapeutics, Inc. by email at safety@vitruvias.com or by phone at (256) 239-9373 Monday through Friday from 9 a.m. to 5 p.m. CT. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

[Read the current instructions](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential)

## Before changing a medicine

Follow urgent instructions in the current official recall notice. Speak to your pharmacist or prescriber before stopping or changing a prescribed medicine.

Talk to your doctor or pharmacist if you have questions or concerns about your medicine. [FDA medication recall guidance](https://www.fda.gov/drugs/drug-recalls/understanding-drug-recalls-what-know-and-what-do)

## Related records

[Medications records](https://isitonrecall.com/category/medications/) [VITRUVIAS THERAPEUTICS INC records](https://isitonrecall.com/brand/vitruvias-therapeutics-inc/)